Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...

The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

AngioDynamics Inc. (NASDAQ : ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

Healthcare Analysts, along with Dr. David Eichenbaum, discuss the current state and future direction in Geographic Atrophy (GA) (relevant ...

After several on-again, off-again tariff threats, U.S. President Donald Trump is scheduled later today to announce what is expected to be country-by-country tariffs in an effort to address U.S. trade ...